Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies - Archive ouverte HAL Access content directly
Journal Articles Haematologica Year : 2017

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (8) , (9) , , (10) , (11) , (12) , , (13) , (14) , (14) , (1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Christian Recher
Laure Stalnikiewicz
  • Function : Author
Hervé Dombret
Norbert Vey
Marie Sebert
  • Function : Author

Dates and versions

hal-01655899 , version 1 (05-12-2017)

Identifiers

Cite

Lionel Adès, Thomas Prebet, Aspasia Stamatoullas, Christian Recher, Romain Guiéze, et al.. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies. Haematologica, 2017, 102 (4), pp.728 - 735. ⟨10.3324/haematol.2016.151894⟩. ⟨hal-01655899⟩
317 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More